Kinnari Patel
President at ROCKET PHARMACEUTICALS, INC.
Net worth: 8 M $ as of 2024-04-29
Kinnari Patel active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Chief Operating Officer | 2018-01-03 | - |
| Chief Tech/Sci/R&D Officer | 2024-03-26 | - | |
| President | - | - |
Career history of Kinnari Patel
Former positions of Kinnari Patel
| Companies | Position | Start | End |
|---|---|---|---|
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Chief Operating Officer | 2017-12-31 | 2021-01-31 |
| General Counsel | 2016-03-31 | 2017-11-30 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2010-10-31 | 2014-03-31 |
Training of Kinnari Patel
| University of the Sciences in Philadelphia | Doctorate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Statistics
International
| United States | 6 |
Operational
| Chief Operating Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Kinnari Patel
- Experience